Guidance Document for Industry - Review of Drug Brand Names

To provide market authorization holders direction on the process to be followed and information to be submitted to Health Canada regarding the potential for a proposed name to be misleading or confused with another product authorized for use in Canada with the aim of preventing medication errors.

Publisher
Health Canada
Resources
2
Catalogue metadata updated
2021-07-07

Data overview

Formats
HTML
File languages
English, French

Official sources and licences

Resources

Related open data